Nanobodies for Medical Imaging: About Ready for Prime Time?
| العنوان: | Nanobodies for Medical Imaging: About Ready for Prime Time? |
|---|---|
| المؤلفون: | Shruti Mishra, Louise Clark, Léa Berland, Lauren Kim, Paul Hofman, Omar Abousaway, Mohammad Rashidian, Andrea Mines |
| المصدر: | Biomolecules Biomolecules, Vol 11, Iss 637, p 637 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Diagnostic Imaging, cancer-specific markers, Locally advanced, Review, Bioinformatics, Microbiology, Biochemistry, Antibody fragments, Radiolabeled Antibodies, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Medical imaging, Medicine, Humans, Radionuclide imaging, VHHs, Radionuclide Imaging, Molecular Biology, Diagnostic Techniques and Procedures, Immuno pet, business.industry, immune checkpoint imaging, Cancer, SPECT/CT, Single-Domain Antibodies, medicine.disease, molecular imaging, QR1-502, nanobodies, 030104 developmental biology, 030220 oncology & carcinogenesis, Positron-Emission Tomography, immuno-PET, Molecular imaging, business |
| الوصف: | Recent advances in medical treatments have been revolutionary in shaping the management and treatment landscape of patients, notably cancer patients. Over the last decade, patients with diverse forms of locally advanced or metastatic cancer, such as melanoma, lung cancers, and many blood-borne malignancies, have seen their life expectancies increasing significantly. Notwithstanding these encouraging results, the present-day struggle with these treatments concerns patients who remain largely unresponsive, as well as those who experience severely toxic side effects. Gaining deeper insight into the cellular and molecular mechanisms underlying these variable responses will bring us closer to developing more effective therapeutics. To assess these mechanisms, non-invasive imaging techniques provide valuable whole-body information with precise targeting. An example of such is immuno-PET (Positron Emission Tomography), which employs radiolabeled antibodies to detect specific molecules of interest. Nanobodies, as the smallest derived antibody fragments, boast ideal characteristics for this purpose and have thus been used extensively in preclinical models and, more recently, in clinical early-stage studies as well. Their merit stems from their high affinity and specificity towards a target, among other factors. Furthermore, their small size (~14 kDa) allows them to easily disperse through the bloodstream and reach tissues in a reliable and uniform manner. In this review, we will discuss the powerful imaging potential of nanobodies, primarily through the lens of imaging malignant tumors but also touching upon their capability to image a broader variety of nonmalignant diseases. |
| اللغة: | English |
| تدمد: | 2218-273X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96302dfb50505b3d4c829c03bb928ed4Test http://europepmc.org/articles/PMC8146371Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....96302dfb50505b3d4c829c03bb928ed4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2218273X |
|---|